Recent clinical trials have shown promise of sodium‐glucose cotransporter 2 (SGLT2) inhibitors in management of CKD associated with or without type 2 diabetes (Kelly et al., 2019; Nespoux & Vallon, 2020). Here, SLC5A2 is linked to chronic kidney disease.